The rally in SMMT stock is driven by encouraging updates on its oncology candidate, which has the potential to become the ...

There has been expectation that the antibody could be made available at a discount to Merck & Co's PD-1 inhibitor Keytruda (pembrolizumab), which dominates first-line NSCLC treatment, offering an ...

Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus’ broadly targeted, short duration ...

BeiGene confirmed today that Novartis has pulled out of a partnership on PD-1 inhibitor tislelizumab, two and half years after paying $650 million upfront for ex-China rights to the cancer ...

Indaptus Therapeutics (INDP) announced a clinical supply agreement with BeiGene (BGNE). Building on Indaptus’ preclinical observation ...

Under Indaptus' clinical supply agreement with BeiGene, the New York biotechnology company plans to advance human clinical evaluation of its cancer treatment -- called Decoy20, which is being studied ...

编者按：随着免疫治疗被越来越多的临床医生关注和应用，免疫调节治疗在感染和重症领域的应用也越来越广泛。胸腺法新是一种由28个氨基酸组成的生物活性多肽，具有免疫调节作用，主要通过促进T淋巴细胞的发育和成熟，增强机体的细胞免疫和体液免疫功能。胸腺法新作为经 ...

抗体（Antibody）是蛋白质疗法的主要类型，目前全球已有超过160种抗体药获批上市，预计在未来五年内市场价值将达到4450亿美元。尽管制药行业对此非常感兴趣，但治疗性抗体的开发仍然依赖于动物 免疫 ...

As companies roll out data showing the power and improved safety profile of antibodies that target two antigens, analysts say ...

After raising $42 million in a series C1 round, Lanova Medicines Ltd. is advancing its lead phase III antibody-drug conjugate LM-302 that targets Claudin 18.2, as well as LM-299, an anti-PD-1/VEGF ...

Promising results from the anti–LAG-3/anti–PD-1 combo for melanoma, FDA approval of inavolisib for PIK3CA-mutant breast cancer, significant survival benefits from talazoparib and enzalutamide in ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...